Follow Neurocrine Biosciences to never miss an important update.
On September 28, the company appointed Dr. Eiry Roberts to the role of Chief Medical Officer. She replaces Dr. Sanjay Keswani, who reached a mutual agreement with the board to step down on September 25. Dr. Roberts is a familiar face at the company, having previously served in senior leadership roles before this appointment.
For a biotech company, the Chief Medical Officer is a critical role that oversees the clinical trials and regulatory approvals for new drugs. While the sudden departure of Dr. Keswani is a shift, the return of an experienced leader like Dr. Roberts suggests the company is focused on keeping its deep pipeline of brain and hormonal treatments on track.
Source: 8-K filing
RBC Capital set its target for the stock at $198. This is slightly lower than the average target of $203 among all analysts who follow the company. Even with the lower target, the firm expects the stock to rise significantly from its current price of about $156.
Source: RBC Capital
Deutsche Bank lowered its price target from $190 to $165. This is a target tweak rather than a change in rating, meaning the firm's overall view on the stock has not shifted. Even with this lower target, the bank still sees the stock as worth more than its current price of about $152. Other analysts remain more optimistic, with the average target across all firms sitting at $203. For a long-term owner, these individual target changes are routine and often reflect short-term market swings rather than a change in the company's ability to develop and sell its brain and hormonal disorder treatments.
Source: Deutsche Bank
The company has moved its experimental obesity treatment, NBIP-1968, into Phase 1 clinical trials. This is the first stage of testing in humans, focusing on whether the drug is safe and how well people tolerate it. The drug is a triple agonist, meaning it targets three different hunger-related hormones at once to help with weight loss.
This move shows Neurocrine is trying to expand beyond brain health and into the fast-growing metabolic market. While it is very early in the process and years away from a potential launch, success here would give the company a foothold in one of the largest categories in medicine.
Source: PRNewsWire
Specialists in Prader-Willi Syndrome, a rare genetic condition that causes constant hunger and growth issues, have raised concerns about the safety of Vykat XR. They cited serious adverse events, which are medical problems that occur during a drug trial that may or may not be caused by the treatment itself.
While this drug is only one part of the company's pipeline, safety warnings in rare disease treatments can lead to stricter labels or delays from regulators. We are watching to see if these reports impact the drug's path to approval or its use in patients.
Source: Reuters
Management has struggled to set a predictable bar, with results often swinging far above or below expectations as the company balances high research costs against drug sales.
| Expectation | |
|---|---|
| EPS | $2.59 |
| Revenue | $1.05B |
Follow Neurocrine Biosciences to get the latest and most important updates.
Follow NBIX